Pulmonary doses CLD did not extend beyond 2 5 cm, regardless of w

A cumulative DVH representing the typical change 3Methyladenine between FB and DIBH in the dose distributions of the PTV and relevant normal tissues is shown in Figure 1. Pulmonary doses CLD did not extend beyond 2.5 cm, regardless of whether the patient SB-715992 manufacturer was in a FB or in a DIBH state.. No statistically significative difference in CLD values was found between DIBH and FB (p = 0.99). A significant (p = 0.04) 28.7% increase in the patient averaged ILV was found in DIBH with repect to FB,

however when the normalized ILV averaged over all patients was taken into account a 23.0% decrease was found, as shown in Table 1. Table 1 Absolute lung volume, ILV and percentage normalized ILV in FB and DIBH   Absolute lung volume (cm3) ILV (cm3) Normalized ILV (%) Patient # DIBH FB DIBH FB DIBH FB 1 1822.47 1428.66 81.10 67.29 4.45 4.71 2 2580.95 1313.33 97.56 43.34 3.78 3.30 3 2659.73 1539.35 199.48 180.72 7.50 11.74

4 1660.88 1165.16 71.75 59.19 4.32 5.08 5 2342.99 1483.92 75.21 Entinostat cell line 71.97 3.21 4.85 6 1928.90 1068.35 192.89 122.54 10.00 11.47 7 2309.26 1301.86 177.12 118.99 7.67 9.14 8 2156.90 1209.99 64.06 81.19 2.97 6.71 All Pt Average 2182.76 1313.83 119.90 93.15 5.49 7.13 The mean (range) and p-values of IL mean dose (Dmean) and IL volumes receiving more than 10 Gy (V10) and 20 Gy (V20) are shown in Table 2 for FB and DIBH for both the conventional and the hypofractionated schedules. Table 2 Ipsilateral mean lung dose and lung volumes receiving more than 10 Gy (V 10 ) and 20 Gy (V 20 )   Conventional fractionation Hypofractionation   DIBH FB p-value DIBH FB p-value Dmean (Gy) 4.64 5.51 0.0505 3.15 3.75 0.0505 (3.32 – 6.11) (3.54 – 8.84) (2.25 – 4.16) (2.40 – 6.01) V10 (%) 9.08 11.54 0.0520

8.32 10.70 0.0405 (5.52 – 15.44) (6.46 – 19.46) (4.93 – 14.22) (5.79 – 17.92) V20 (%) 6.11 8.13 0.0398 5.71 7.65 0.0406 (3.43 – 1.06) (3.97 – 14.11) (3.14 – 10.52) (3.62 – 13.41) In the conventional fractionation the IL mean dose was reduced by 18.8% in DIBH. The mean values for V10 were 11.54% and 9.08% for FB and DIBH, respectively, which amounted to a 21.3% decrease in DIBH. In the hypofractionated schedule the IL mean dose was reduced by 16.0% in DIBH the mean values PAK6 of V10 were 10.7% and 8.32%, respectively i.e. showed a 22.2% decrease in DIBH. The V20 values were 8.13% and 6.11% for FB and DIBH, respectively, for the conventional schedule (24.8% decrease in DIBH). For hypofractionaction they were 7.65% and 5.71%, respectively (25.4% decrease in DIBH).

Comments are closed.